2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatientsAcquired Disorders of Hypomagnesemia
Rosner M, Ha N, Palmer B, Perazella M. Acquired Disorders of Hypomagnesemia. Mayo Clinic Proceedings 2023, 98: 581-596. PMID: 36872194, DOI: 10.1016/j.mayocp.2022.12.002.Peer-Reviewed Original ResearchConceptsReduced glomerular filtration rateBody storesBody magnesium storesGlomerular filtration rateSerum magnesium levelsTotal body storesDevelopment of symptomsIntravenous replacementOrgan dysfunctionMagnesium disordersRenal lossMagnesium replacementFiltration rateSevere casesMagnesium storesHypomagnesemiaClinical experienceClinical practiceMagnesium levelsAcquired disordersAmphotericin BMagnesium handlingOptimal managementMedicationsLaboratory assessment
2022
Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity
Qian L, Menez S, Hu D, Weinstein J, Melchinger H, Thiessen-Philbrook H, Luciano R, Turner J, Perazella M, Villalobos C, Shaw M, Wilson F, Parikh C, Moledina D. Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity. Kidney360 2022, 4: 98-101. PMID: 36700910, PMCID: PMC10101611, DOI: 10.34067/kid.0006602022.Peer-Reviewed Original ResearchImmune checkpoints inhibitors and its link to acute kidney injury and renal prognosis
Kanbay M, Yildiz AB, Siriopol D, Vehbi S, Hasbal NB, Kesgin YE, Celayir M, Selcukbiricik F, Covic A, Perazella MA. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. International Urology And Nephrology 2022, 55: 1025-1032. PMID: 36282399, DOI: 10.1007/s11255-022-03395-y.Peer-Reviewed Original ResearchConceptsAcute kidney injuryImmune checkpoint inhibitorsSolid organ malignanciesCheckpoint inhibitorsKidney injuryOrgan malignanciesNephrotoxic agentsSingle-center retrospective cohort studyType of ICIBaseline serum creatinine levelAcute interstitial nephritisLocation of malignancyRetrospective cohort studySerum creatinine levelsKidney function recoveryRenal replacement therapyUrinary tract obstructionRisk of mortalityICPI treatmentRenal prognosisTract obstructionCohort studyCreatinine levelsFive patientsInterstitial nephritisDiagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers B, Leaf DE, Porta C, Soler MJ, Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nature Reviews Nephrology 2022, 18: 794-805. PMID: 36168055, DOI: 10.1038/s41581-022-00630-8.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute kidney injuryKidney injuryKidney biopsyAcute tubulo-interstitial nephritisImmune-related adverse eventsConcomitant anticancer therapyTubulo-interstitial nephritisEffector T cellsEvaluation of patientsLoss of toleranceCheckpoint inhibitorsPartial remissionPermanent discontinuationAdverse eventsMost patientsAppropriate treatmentEarly initiationT cellsClinical practiceFavorable responsePatientsAccurate diagnosisCancer treatmentAnticancer therapyDrug-Induced Acute Kidney Injury
Perazella MA, Rosner MH. Drug-Induced Acute Kidney Injury. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1220-1233. PMID: 35273009, PMCID: PMC9435983, DOI: 10.2215/cjn.11290821.Peer-Reviewed Original ResearchConceptsKidney injuryTubular injuryDrug-induced acute kidney injuryT cell-mediated immune responsesDrug-related kidney injuryCell-mediated immune responsesAcute interstitial nephritisDirect tubular injuryTreatment of AKIAcute kidney injuryAcute tubular injuryIntensive care unitInduction of inflammationAKI riskIntratubular obstructionTubulointerstitial injuryInterstitial nephritisCare unitInflammation leadInjury resultsCommon causeImmune responseHospital wardsProximal tubulesAKIDrug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List?
Perazella MA, Juncos LA. Drug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List? Kidney360 2022, 3: 550-553. PMID: 35582186, PMCID: PMC9034826, DOI: 10.34067/kid.0007882021.Peer-Reviewed Original ResearchMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2020
Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020, 298: 202903. PMID: 33170103, DOI: 10.1148/radiol.2020202903.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisNational Kidney FoundationKidney diseaseGroup IIConsensus statementKidney FoundationAmerican CollegeRisk of NSFContrast mediumAcute kidney injuryAdvanced kidney diseaseCare of patientsGadolinium-based contrast mediaSimultaneous joint publicationKidney injuryDialysis initiationClinical indicationsSystemic fibrosisPatientsIntravenous gadoliniumUnconfounded casesDiseasePotential harmRadiologyRiskCOVID-19 therapeutic options for patients with kidney disease
Izzedine H, Jhaveri KD, Perazella MA. COVID-19 therapeutic options for patients with kidney disease. Kidney International 2020, 97: 1297-1298. PMID: 32317113, PMCID: PMC7271263, DOI: 10.1016/j.kint.2020.03.015.Peer-Reviewed Original ResearchKidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary.
Perazella M. Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary. Kidney360 2020, 1: 166-168. PMID: 35378019, PMCID: PMC8809261, DOI: 10.34067/kid.0001072019.Peer-Reviewed Original ResearchNomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International 2020, 97: 1117-1129. PMID: 32409237, DOI: 10.1016/j.kint.2020.02.010.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseGlomerular filtration rateKidney diseaseKidney functionKDIGO definitionConsensus conferenceSeverity of CKDEnd-stage kidney diseaseAcute kidney diseaseAbsence of symptomsGlobal Outcomes (KDIGO) Consensus ConferenceKDIGO guidelinesKidney injuryKidney failureKidney measuresFiltration rateWorldwide burdenGlobal outcomeKidney structureDiseaseHealth communitySeverityFollowing recommendationsMore effective communicationIntroduction to Kidney 360.
Allon M, Juncos LA, Perazella MA. Introduction to Kidney 360. Kidney360 2020, 1: 3-4. PMID: 35372862, PMCID: PMC8808487, DOI: 10.34067/kid.0000492019.Peer-Reviewed Original Research
2015
Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal Of Kidney Diseases 2015, 66: 857-868. PMID: 25943718, DOI: 10.1053/j.ajkd.2015.02.340.Peer-Reviewed Original ResearchConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsLong-term kidney injuryManagement of TMACell damageGrowth factor agentsAnti-VEGF agentsEndothelial cell damageType I agentsChemotherapy regimensDrug interruptionFactor agentsKidney injuryImmunologic basisClinical courseFunctional recoveryImmunosuppressive agentsKidney functionCertain malignanciesI agentsPhysician guidanceAnticancer therapySuccessful diagnosis
2010
Experience with outpatient computed tomographic-guided renal biopsy.
Margaryan A, Perazella MA, Mahnensmith RL, Abu-Alfa AK. Experience with outpatient computed tomographic-guided renal biopsy. Clinical Nephrology 2010, 74: 440-5. PMID: 21084047, DOI: 10.5414/cnp74440.Peer-Reviewed Original ResearchConceptsNative kidney biopsiesKidney biopsyRenal biopsyPost-biopsy observation periodInpatient observation periodObservation periodLow complication rateTime of admissionYale-New Haven Medical CenterDuration of procedureInstances of deathHemoglobin concentration changesDetectable bleedingSerum creatinineComplication rateMean ageRenal sizeAdequate tissueMedical CenterOutpatient unitDiagnostic tissueBiopsyLaboratory dataTransfusionPatients
2001
COX-2 Inhibitors and the Kidney
Perazella M. COX-2 Inhibitors and the Kidney. Hospital Practice 2001, 36: 43-56. PMID: 11263799, DOI: 10.3810/hp.2001.03.230.Peer-Reviewed Original ResearchNSAIDs and the Kidney Revisited: Are Selective Cyclooxygenase-2 Inhibitors Safe?
Eras J, Perazella M. NSAIDs and the Kidney Revisited: Are Selective Cyclooxygenase-2 Inhibitors Safe? The American Journal Of The Medical Sciences 2001, 321: 181-190. PMID: 11269794, DOI: 10.1097/00000441-200103000-00005.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsCOX-2 selective inhibitorsSelective cyclooxygenase-2 inhibitorRenal effectsCyclooxygenase-2 inhibitorNonselective nonsteroidal anti-inflammatory drugsSelective nonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsAdverse renal effectsBaseline patient characteristicsAdverse gastrointestinal effectsCOX-1/COXCyclooxygenase enzyme activityAnti-inflammatory drugsCOX-2 inhibitorsCOX-2 enzymePatient characteristicsGastrointestinal effectsChronic painGastric erosionsInflammatory conditionsClinical studiesClinical investigationKidney tissueKidney
2000
Drug-induced hyperkalemia: old culprits and new offenders
Perazella M. Drug-induced hyperkalemia: old culprits and new offenders. The American Journal Of Medicine 2000, 109: 307-314. PMID: 10996582, DOI: 10.1016/s0002-9343(00)00496-4.Peer-Reviewed Original ResearchConceptsDrug-induced hyperkalemiaRisk of hyperkalemiaRenal potassium excretionRenal impairmentPatient characteristicsPotassium excretionPotassium handlingPotassium loadPrescribed medicationsExcessive ingestionHyperkalemiaCounter drugsOld culpritsNutritional supplementsPotassium homeostasisMedicationsPatientsDrugsCellular uptakeInfusionAbnormalitiesExcretionPhysiciansImpairmentIngestionTrimethoprim-Induced Hyperkalaemia
Perazella M. Trimethoprim-Induced Hyperkalaemia. Drug Safety 2000, 22: 227-236. PMID: 10738846, DOI: 10.2165/00002018-200022030-00006.Peer-Reviewed Original ResearchConceptsRenal potassium excretionPotassium excretionHigh urinary flow ratesPotassium homeostasisManagement of hyperkalaemiaGlomerular filtration ratePotassium-sparing diuretic amilorideUrinary flow rateRecognition of patientsDistal nephron cellsTrimethoprim therapyRenal impairmentCommon complicationLoop diureticsEpithelial sodium channelIntravenous fluidsVolume repletionAdverse reactionsFiltration rateRisk factorsStandard dosageAntikaliuretic effectHyperkalaemiaIsotonic fluidsDistal nephron
1999
Crystal-induced acute renal failure
Perazella M. Crystal-induced acute renal failure. The American Journal Of Medicine 1999, 106: 459-465. PMID: 10225250, DOI: 10.1016/s0002-9343(99)00041-8.Peer-Reviewed Original ResearchConceptsAcute renal failureRenal insufficiencyRenal failureVolume repletionAppropriate drug dosingIntrarenal crystal depositionAcute renal insufficiencyIntravascular volume depletionAdditional risk factorsHigh urinary flowDialytic supportUrinary flowRisk factorsVolume depletionDrug dosingDrug dosesCrystal depositionIntratubular precipitationInsufficiencyUrineMedicationsRepletionFurther exposureFailureHuman urine